Professor Robert Clarke
Research groups
- Causes and consequences of heart failure in Chinese adults (MRC PHRU)
- Causes and consequences of heart failure in Chinese adults (MRC PHRU)
- Causes and consequences of frailty in 0.5M adults living in China
- Incidence, determinants and prognosis of heart failure in Chinese adults (MRC PHRU)
- Patterns, determinants and prognosis of multi-morbidity associated with major cardiometabolic diseases in Chinese adults
- Prediction of cardiovascular disease in 0.5M adults living in the UK: evaluation of novel risk factors using modern statistical approaches
Websites
-
University of Cambridge
External Examiner in Epidemiology
-
London School of Hygiene and Tropical Medicine
External Examiner in Epidemiology
-
University College Dublin
External Examiner in Epidemiology
-
Faculty of Public Health Medicine, Royal College of Physicians of Ireland
External Examiner in Epidemiology
-
Swedish Cardiopulmonary Bioimage Study (SCAPIS)
Scientific Advisory Board
-
Irish Longitudinal Study on Aging (TILDA)
Scientific Advisory Board
Robert Clarke
MD, FRCP, FFPH, FFPHI, MSc, DCH
Professor of Epidemiology and Public Health Medicine
- Clinical Trial Service Unit and Epidemiological Studies Unit
Robert Clarke is a Professor of Epidemiology and Public Health Medicine at the Clinical Trial Service Unit (CTSU), Nuffield Department of Population Health, University of Oxford and Consultant in Public Health Medicine and Director of the MSc course in Global Health Science. He qualified in clinical medicine in Ireland and worked for 5 years in internal medicine and 4 years in cardiology. After 2 years in clinical pharmacology at Vanderbilt University, Nashville, USA, he joined CTSU in 1991 and specialised in Cardiovascular Epidemiology.
His main research interests are to understand the importance of classical and novel risk factors for occlusive vascular diseases. He led several large observational studies and meta-analyses of observational studies and randomized trials (eg, Whitehall study, PROCARDIS, CARDIoGRAMplusC4D, B-Vitamin Treatment Trialists’ Collaboration and the BEST-D trial). He also worked extensively on the Prospective Studies Collaboration and the China Kadoorie Biobank (CKB) study. He currently leads a research programme to assess the importance of blood pressure, blood lipids, and novel biomarkers (including genetic markers, cytokines, proteomics and metabolomics) for occlusive vascular diseases in the CKB study. His work has been widely cited (200 publications, H-index of 54) and is listed in Tomson Reuters’ Most Influential Scientific Minds 2014.
Recent publications
-
Risk prediction of ischemic heart disease using plasma proteomics, conventional risk factors and polygenic scores in Chinese and European adults.
Journal article
Mazidi M. et al, (2024), Eur J Epidemiol
-
Proteo-genomic analyses in relatively lean Chinese adults identify proteins and pathways that affect general and central adiposity levels.
Journal article
Iona A. et al, (2024), Commun Biol, 7
-
Predictive value of 8-year blood pressure measures in intracerebral haemorrhage risk over 5 years.
Journal article
Zhang Y. et al, (2024), Eur J Prev Cardiol, 31, 1702 - 1710
-
Measured and genetically predicted protein levels and cardiovascular diseases in UK Biobank and China Kadoorie Biobank.
Journal article
Lind L. et al, (2024), Nat Cardiovasc Res
-
Milk intake, lactase non-persistence and type 2 diabetes risk in Chinese adults.
Journal article
Kakkoura MG. et al, (2024), Nat Metab